Korro Bio's COO Todd Chappell Sells Shares

Todd Chappell, the Chief Operating Officer of Korro Bio, Inc., sold 3,168 shares of the company on June 16, 2026. The shares were sold at an average price of $10.83, amounting to a total transaction value of $34,309. This sale was not part of a pre-planned trading program.

Other Institutional Activity in Korro Bio

Several institutional investors have been active in Korro Bio recently. Lynx1 Capital Management LP significantly increased its stake by adding 860,381 shares, ending with 1,538,296 shares valued at approximately $17.4 million. NEA Management Company, LLC also boosted its holdings by 207,100 shares to a total of 1,297,893 shares, valued at about $14.7 million. Atlas Venture Life Science Advisors, LLC maintained its position with 1,137,149 shares worth roughly $12.9 million. Meanwhile, Balyasny Asset Management L.P. and Venrock Adviser, LLC both acquired new positions, each holding over 1 million shares valued at $11.8 million and $11.4 million, respectively.

Korro Bio, Inc. Stock Down 14.4%

Shares of NasdaqCM:KRRO traded at $10.66. Korro Bio has a market capitalization of approximately $159.4 million. The company's stock has been quite volatile, with a 52-week range between $5.20 and $55.89. The stock's 50-day moving average is $12.21, while the 200-day moving average is $17.76. The company's current ratio is a robust 8.13, and its quick ratio stands at 7.71, indicating strong short-term liquidity. However, the company is not currently profitable, reflected in a forward P/E ratio that is not meaningful.

Insider Buying and Selling at Korro Bio, Inc.

In addition to Todd Chappell's sale, several other insiders sold shares on the same day. Jeffrey Cerio, the General Counsel, sold 6,609 shares, and Oliver Dolan, the Senior Vice President of Finance, sold 3,383 shares. Loic Vincent, the Chief Scientific Officer, also sold 3,418 shares. These transactions were not planned sales.

Analysts Set New Price Targets

Analysts have been active in setting new price targets for Korro Bio. On May 19, 2026, HC Wainwright & Co. maintained a 'buy' rating with a $15 target. Citigroup initiated coverage with a 'buy' rating and a $21 target on May 18. Cantor Fitzgerald and Raymond James both maintained and upgraded their ratings to 'buy', with targets of $22 and $23, respectively.

About Korro Bio

Korro Bio, Inc. is a biotechnology company based in Cambridge, Massachusetts. It focuses on developing genetic medicines using RNA editing technology, aiming to treat both rare and common diseases. Its lead product candidate, KRRO-121, targets hyperammonemia. The company also explores treatments for conditions like Parkinson's disease and amyotrophic lateral sclerosis. Korro Bio collaborates with Novo Nordisk to address cardiometabolic diseases. Founded in 2018, the company employs 49 people.

Bottom Line

Korro Bio's insider selling, including that by COO Todd Chappell, is a notable event, though it doesn't necessarily indicate a negative outlook. The stock remains volatile, with significant institutional interest and analyst attention. Investors should consider these dynamics, keeping in mind that insider trades are reported after the fact.